IL-6 polymorphism in non-small cell lung cancer: a prognostic value?

• Type: Article in International Scientific Journal
• Date: 2015

Authors

Gomes, M (Author) Other; Coelho, A (Author) Other; Araujo, A (Author) Other; Azevedo, A (Author) Other; Teixeira, AL (Author) Other; Catarino, R (Author) Other; Rui Medeiros (Author) ICBAS

Journal

Title: Tumor Biology

Vol. 36

Pages: 3679-3684

ISSN: 1010-4283

Publisher: SAGE

Indexing

ISI Web of Knowledge - 28 Citations

Scopus - 31 Citations

Other information

Authenticus ID: P-00G-24X

DOI: 10.1007/s13277-014-3006-6

Abstract (EN): Lung cancer was found to be the most commonly diagnosed cancer, as well as the primary cause of cancer-related mortality for males worldwide and the second leading cause of cancer-related deaths for women. Cytokines are fundamental for several biological processes-associated malignant tumors. The IL-6 is a cytokine involved in the regulation of cellular functions including processes associated with cancer, such as proliferation, apoptosis, angiogenesis, and differentiation. Furthermore, IL-6 is a potent pleiotropic inflammatory cytokine that is considered a key growth-promoting and antiapoptotic factor. The polymorphism -aEuro parts per thousand 174G/C SNP is a G to C transition in the -174 position of the promoter region of the IL-6 gene. The aim of our study was to evaluate the influence of -174G/C polymorphism in clinical outcome of non-small cell cancer (NSCLC) patients. DNA was extracted from peripheral blood of 424 patients diagnosed with cytologically or histologically NSCLC. The characterization of IL-6 -174G/C genotypes was performed by PCR-RFLP (NlaIII). IL-6 polymorphism's genotypes were divided according to functional activity, so the G carriers (CG/GG) is the high-producer IL-6, and CC genotype is the low-producer IL-6. Regarding survival, we verify that patients with genotypes carrying the G allele (CG/GG) had a statistically significant diminished survival when compared with patients with CC genotype (62.79 and 42.31 months, respectively; P = 0.032). In the promoter region of the IL-6 gene, polymorphic variants were located and may be responsible for alterations in transcription that consequently affect serum levels of the cytokine. With our study, we demonstrated that genetic variant (-174G/G and G/C) can be responsible for changes in prognosis of NSCLC patients.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 6